Background: Hepatic steatosis is a common incidental finding on emergency department (ED) imaging studies, occurring in up to 10% of studies, and carries significant long-term morbidity. Frequently considered an unimportant finding, it is unknown how often ED patients are informed of hepatic steatosis. Our objective was to examine hepatic steatosis inclusion in ED discharge materials.
Methods: Data from discharged patients at an urban academic ED (>90,000 visits) with abdominal imaging (computed tomography or ultrasound) from 2019 to 2022 were screened. Patients with radiology reports documenting hepatic steatosis were included. Two trained data abstractors analyzed discharge materials and coded disclosure of steatosis (present/absent). Data abstraction also noted how the finding was included (e.g., follow-up instructions, provision of radiology report). Factors associated with patient disclosure were examined through regression models including age, race, ethnicity, insurance, number of imaging studies during encounter, type of imaging study, and inclusion of hepatic steatosis in the impression section of radiology report.
Results: Of 10,677 radiology reports, 1209 (11.3%) had documented hepatic steatosis. The mean (±SD) age was 47.1 (±14.1) years; 56.4% were female, 53.5% were White, and 30.7% Hispanic. Only 173 of 1209 patients (14.3%) received any discharge documentation of hepatic steatosis. In 65% of cases where disclosure occurred, the imaging report was pasted verbatim into discharge material. There were no significant differences in discharge documentation by demographic groups. Mention within the radiology report impression (rather than the report body alone) occurred in 73.8% of records and was the strongest predictor of disclosure to patients (adjusted odds ratio 2.18, 95% confidence interval 1.39-3.54).
Conclusions: Despite the high prevalence of hepatic steatosis in radiology reports, rates of documentation in patient-facing discharge materials are notably low, exposing a possible communication failure with consequences for diagnosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/acem.15044 | DOI Listing |
PLoS One
January 2025
Department of Preventive Medicine and Public Health, Catholic Kwandong University College of Medicine, Gangneung, South Korea.
Background And Aims: We investigated associations between body mass index (BMI) and hepatocellular carcinoma (HCC) in patients with hepatitis B (HBV) C (HCV) virus infection, alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), and liver cirrhosis (LC).
Methods: We followed 350,608 Korean patients with liver disease who underwent routine health examinations from 2003-2006 until December 2018 via national hospital discharge records. Multivariable adjusted hazard ratios (HRs) per 5-kg/m2 BMI increase (BMI ≥25 kg/m2) for HCC risk were calculated using Cox models.
Rev Paul Pediatr
January 2025
Universidade Federal do Paraná, Curitiba, PR, Brazil.
Objective: To investigate the presence of metabolic dysfunction-associated fatty liver disease (MAFLD) and gallbladder abnormalities in a sample of people with Down syndrome in Brazil.
Methods: This is a retrospective study using medical charts involving Down syndrome patients, diagnosed by karyotype, aged over 5 years, who underwent abdominal ultrasound and were monitored by the same professional in a clinic in Curitiba, Brazil. Data spanned January 1995 to September 2023; all cases with no use of alcohol or hepatotoxic medications.
J Imaging Inform Med
January 2025
Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan.
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver condition characterized by excessive hepatic fat accumulation. Early diagnosis is crucial as NAFLD can progress to more severe conditions like steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma without timely intervention. While liver biopsy remains the gold standard for NAFLD assessment, abdominal ultrasound (US) imaging has emerged as a widely adopted non-invasive modality due to convenience and low cost.
View Article and Find Full Text PDFCurr Nutr Rep
January 2025
Faculty of Pharmaceutical Science, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, Assam, India, PIN - 781026.
Purpose Of Review: The term metabolic dysfunction-associated steatotic liver disease (MASLD) refers to a group of progressive steatotic liver conditions that include metabolic dysfunction-associated steatohepatitis (MASH), which has varying degrees of liver fibrosis and may advance to cirrhosis, and independent hepatic steatosis. MASLD has a complex underlying mechanism, with patients exhibiting diverse causes and phases of the disease. India has a pool prevalence of MASLD of 38.
View Article and Find Full Text PDFJ Gen Intern Med
January 2025
College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.
Background: Type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD), which have a reciprocal relationship compounded by obesity, are highly prevalent in the Middle East affecting morbidity, mortality, and healthcare costs.
Objective: This study aimed to assess the severity of MASLD and liver fibrosis among adult Emirati patients with long-standing T2DM.
Design And Participants: This cross-sectional study used noninvasive methods to assess the severity of MASLD and fibrosis progression in an adult cohort of Emirati patients (N = 546) with a mean T2DM duration of 16 years.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!